Parvovirus B19 Vaccine

Parvovirus B19 (B19V) infection causes fifth disease, a disease characterized by rashes to the face and other parts of the body that primarily affects children. However, adults can also develop fifth disease and it can lead to more severe conditions. Patients that are immunocompromised, such as those who are HIV infected, organ transplant recipients, and cancer patients, can be particularly susceptible to more severe outcomes from B19V infection. Infection can also cause anemia and in pregnant women, it can lead to hydrops fetalis.

The subject technologies are expression vectors for the production of B19V VP1 and VP2 capsid proteins. Co-expression of the two proteins produce empty virus-like particles (VLPs) that can be used to develop a vaccine against parvovirus B19 and a packaging system for infectious B19V virus. Different expression vectors have been developed and optimized for expression in insects cells and more recently in mammalian cell lines such as 293, Cos7, Hela cells and 293T cells.

Potential Commercial Applications: Competitive Advantages:
Vaccine against parvovirus B19V. There is currently no B19V vaccine on the market.

Development Stage:
  • Early-stage
  • Pre-clinical
  • Clinical
  • In vitro data available
  • In vivo data available (animal)
  • In vivo data available (human)


Neal Young (NHLBI)  ➽ more inventions...

Sachiko Kajigaya (NHLBI)  ➽ more inventions...

Takashi Shimada (NHLBI)  ➽ more inventions...

Ning Zhi (NHLBI)  ➽ more inventions...

Intellectual Property:
U.S. Pat: 6,132,732 issued 2000-10-17
U.S. Pat: 5,916,563 issued 1999-06-29
U.S. Pat: 6,001,371 issued 1999-12-14
U.S. Pat: 6,558,676 issued 2003-05-06
U.S. Pat: 5,827,647 issued 1998-10-27
U.S. Pat: 5,508,186 issued 1996-04-16
US Application No. 13/578,577
US Application No. 07/843,067
PCT Application No. *
PCT Application No. PCT/US91/08310
US Application No. 08/463,332
US Application No. 07/612,672
US Application No. 10/366,810

Bernstein DI, et al. PMID 21807052
Zhi N, et al. PMID 20943969

Collaboration Opportunity:

The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the technology for producing Parvovirus B19 vaccine. For collaboration opportunities, please contact Cecilia Pazman, Ph.D. at

Licensing Contact:
Admin. Licensing Specialist (ALS), Ph.D.
Phone: 301-594-4095

OTT Reference No: E-286-1988-1
Updated: May 7, 2013